AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01497860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
Study NCT02038699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
Study NCT03400033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline vials or bags
Description: 0.9% sodium chloride saline vials or bags administered by the IV route.
Study NCT02443532 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual education
Description: Usual care (individual consultations as routinely performed)
Study NCT02296814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinusitis Hevert SL Tablet
Description: 1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
Study NCT02296814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Sinusitis Hevert SL Tablet
Description: 1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
Study NCT01622946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: 3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
Study NCT03873376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in; Receive offer to order self-sampling kit
Description: Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
Study NCT03873376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out; Receive self-sampling kit unsolicited
Description: Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
Study NCT03873376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control; Receive open reminder to be screened by physician
Description: Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
Study NCT01506505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Agents
Description: Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
Study NCT01622946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
Study NCT02061293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Study NCT02613533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-ocular pressure measurement (IOP)
Description: Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
Study NCT01506505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiovascular Agents
Description: Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
Study NCT01247090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin - Very Low Dose
Description: Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU \* 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
Study NCT01247090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin - Low Dose
Description: Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU \* 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
Study NCT01247090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
Study NCT01690390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib of routine dose
Description: Icotinib of routine dose: 125 mg is administered orally three times per day.
Study NCT01690390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib of high dose
Description: Icotinib: 250 mg is administered orally three times per day.
Study NCT02794272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Study NCT02794272 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS
Study NCT04113473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation.~Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes.
Study NCT03552510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oro-pharyngeal Administration of Mother's Milk
Description: Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
Study NCT02901938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cemented femoral stem
Description: The patients assigned even numbers will undergo implantation of cemented femoral stem.
Study NCT02901938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cannulated compression screws
Description: The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
Study NCT01608100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARCHITECT STAT High Sensitive Troponin I Assay
Description: Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit.
Study NCT02570464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
Study NCT02570464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood drawn
Description: Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
Study NCT02570464 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Blood drawn
Description: Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
Study NCT03304925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study NCT00755742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided.
Study NCT01385124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cannabidiol
Description: Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
Study NCT00755742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided.
Study NCT02684227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02684227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT02684227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02684227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03832686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Coach
Description: The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
Study NCT01934439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 PAAD treatments
Description: Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
Study NCT01483443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oophrectomy
Description: Both oophrectomy
Study NCT02684227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01209910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Subjects in this arm will be able to drink water with some conditions.
Study NCT00196781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CD-ROM-based prostate cancer treatment education
Description: The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
Study NCT00196781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CD-ROM-based prostate ca treatment education+decision tools
Description: The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
Study NCT01760148 — intervention group
Intervention type: DRUG
Intervention: interferon alpha 2b
Description: Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.
Study NCT02367599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Supplement
Description: Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
Study NCT04272398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic elastomeric fabric orthoses
Description: Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
Study NCT04272398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dynamic elastomeric fabric orthoses
Description: Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
Study NCT01574703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: All dosing to have taken place per study A3051123
Study NCT01574703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline tartrate
Description: All dosing to have taken place per study A3051123
Study NCT02838888 — intervention group
Intervention type: DEVICE
Intervention: Automatic polyp detection software
Description: A computer program for the detection of colonic polyps will be used during colonoscopy
Study NCT02061293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Study NCT02061293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement and Taking Action (META)
Description: Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
Study NCT06247267 — intervention group
Intervention type: DRUG
Intervention: Fortesta
Description: Primary/secondary untreated hypogonadism patients receive Fortesta injection, gel and transdermal treatment for 12 months with titration for a serum total T level between 300-600ng/dL.
Study NCT06247267 — intervention group
Intervention type: DRUG
Intervention: Estradiol
Description: Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.
Study NCT06247267 — intervention group
Intervention type: DRUG
Intervention: Fortesta
Description: Female-to-male (FTM) receive Fortesta injection, gel and transdermal treatment for 12 months for hormonal transition period.
Study NCT01493388 — intervention group
Intervention type: DRUG
Intervention: insulin
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician.
Study NCT00908193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic DA VINCI Robot Assisted coelioscopy
Description: Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
Study NCT00908193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional coelioscopy
Description: Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
Study NCT03317509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic (rTMS)
Description: Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
Study NCT02061293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement and Taking Action (META)
Description: Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
Study NCT01243853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-galactosidase
Description: 3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
Study NCT01243853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha-galactosidase
Description: 3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
Study NCT00564876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
Study NCT02866201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal swab
Study NCT01958619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1440mg PQP tablets
Description: Piperaquine phosphate tablets (1440mg)
Study NCT01958619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960mg PQP tablets
Description: Piperaquine phosphate tablets (960mg)
Study NCT01958619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 + TPGS
Description: OZ439 (800mg) + TPGS granules for oral suspension
Study NCT01958619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960mg PQP granules
Description: Piperaquine phosphate granules for oral solution (960mg)
Study NCT01574703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Description: All dosing to have taken place per study A3051123
Study NCT01574703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy Patch
Description: All dosing to have taken place per study A3051123
Study NCT03818334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1000 mg/flask
Study NCT03818334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
Study NCT04066894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Explantation
Description: Undergo lead removal
Study NCT04066894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04066894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00964067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
Study NCT04066894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral Nerve Stimulator
Description: Undergo sacral nerve stimulator implantation
Study NCT04066894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral Nerve Stimulator Battery
Description: Undergo sacral nerve stimulator battery implantation
Study NCT04066894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo sacral nerve stimulator implantation
Study NCT02302118 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagogastrectomy
Description: Esophagogastrectomy
Study NCT00743873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Description: US guided IM injection 3-6mg